Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2008

01-08-2008 | Original Paper

Acid-suppression Therapy Offers Varied Laryngopharyngeal and Esophageal Symptom Relief in Laryngopharyngeal Reflux Patients

Authors: Nobuhiko Oridate, Hiroshi Takeda, Masahiro Asaka, Noriko Nishizawa, Yasushi Mesuda, Mika Mori, Yasushi Furuta, Satoshi Fukuda

Published in: Digestive Diseases and Sciences | Issue 8/2008

Login to get access

Abstract

It is widely accepted that laryngopharyngeal reflux requires more aggressive and prolonged therapy than gastro-esophageal reflux disease. Otolaryngologists often observe that laryngopharyngeal symptoms, such as throat clearing, hoarseness, cough, and globus pharyngeus, are slower to resolve than esophageal symptoms, such as heartburn and regurgitation. The aim of this was to provide empirical evidence to support this observation and to carry out a detailed investigation of the differences between these symptoms. Forty-five patients with laryngopharyngeal and esophageal symptoms received acid-suppression therapy that involved the continuous administration of a proton-pump inhibitor for up to 6 months. We investigated the differences in response to acid-suppression therapy between patients suffering from laryngopharyngeal and esophageal symptoms, respectively, who received upper gastrointestinal endoscopy and were assayed for serum Helicobacter pylori antibodies. The significance of the rate of symptom improvement was estimated by Kaplan–Meier analysis and the logrank test. Laryngopharyngeal symptoms improved significantly more slowly than esophageal symptoms following acid-suppression therapy (49.8 vs. 78.3%, 60 days after the start of acid suppression; P = 0.003). These differences were observed both in patients with erosive esophagitis (P = 0.008) and in H. pylori-seronegative patients (P = 0.001).
Literature
1.
go back to reference Koufman JA (1991) The otolaryngologic manifestations of gastro-esophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 101:1–78PubMedCrossRef Koufman JA (1991) The otolaryngologic manifestations of gastro-esophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 101:1–78PubMedCrossRef
2.
go back to reference Hopkins C, Yousaf U, Pedersen M (2005) Acid reflux treatment for hoarseness (protocol). Cochrane Database Syst Rev 3. Accession no. 00075320-10000000-03935 Hopkins C, Yousaf U, Pedersen M (2005) Acid reflux treatment for hoarseness (protocol). Cochrane Database Syst Rev 3. Accession no. 00075320-10000000-03935
3.
go back to reference Ford CN (2005) Evaluation and management of laryngopharyngeal reflux. J Am Med Assoc 294:1534–1540CrossRef Ford CN (2005) Evaluation and management of laryngopharyngeal reflux. J Am Med Assoc 294:1534–1540CrossRef
4.
go back to reference Book DT, Rhee JS, Toohill RJ, Smith TL (2002) Perspectives in laryngopharyngeal reflux: an international survey. Laryngoscope 112:1399–1406PubMedCrossRef Book DT, Rhee JS, Toohill RJ, Smith TL (2002) Perspectives in laryngopharyngeal reflux: an international survey. Laryngoscope 112:1399–1406PubMedCrossRef
5.
go back to reference Berardi RR (2000) A critical evaluation of proton pump inhibitors in the treatment of gastresophageal reflux disease. Am J Manag Care 6:S491–S505PubMed Berardi RR (2000) A critical evaluation of proton pump inhibitors in the treatment of gastresophageal reflux disease. Am J Manag Care 6:S491–S505PubMed
6.
go back to reference Vaezi MF (2003) Extraesophageal manifestations of gastresophageal reflux disease. Clin Cornerstone 5:32–38PubMedCrossRef Vaezi MF (2003) Extraesophageal manifestations of gastresophageal reflux disease. Clin Cornerstone 5:32–38PubMedCrossRef
7.
go back to reference Park W, Hicks DM, Khandwala F, Richter JE, Abelson TI, Milstein C, Vaezi MF (2005) Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. Laryngoscope 115:1230–1238PubMedCrossRef Park W, Hicks DM, Khandwala F, Richter JE, Abelson TI, Milstein C, Vaezi MF (2005) Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. Laryngoscope 115:1230–1238PubMedCrossRef
8.
go back to reference Oridate N, Takeda H, Yamamoto J, Asaka M, Mesuda Y, Nishizawa N, Mori M, Furuta Y, Fukuda S (2006) Helicobacter pylori seropositivity predicts outcomes of acid suppression therapy for laryngopharyngeal reflux symptoms. Laryngoscope 116:547–553PubMedCrossRef Oridate N, Takeda H, Yamamoto J, Asaka M, Mesuda Y, Nishizawa N, Mori M, Furuta Y, Fukuda S (2006) Helicobacter pylori seropositivity predicts outcomes of acid suppression therapy for laryngopharyngeal reflux symptoms. Laryngoscope 116:547–553PubMedCrossRef
9.
go back to reference Belafsky PC, Postma GN, Koufman JA (2002) Validity and reliability of the Reflux Symptom Index (RSI). J Voice 16:274–277PubMedCrossRef Belafsky PC, Postma GN, Koufman JA (2002) Validity and reliability of the Reflux Symptom Index (RSI). J Voice 16:274–277PubMedCrossRef
10.
go back to reference Belafsky PC, Postma GN, Koufman JA (2001) The validity and reliability of the Reflux Finding Score (RFS). Laryngoscope 111:1313–1317PubMedCrossRef Belafsky PC, Postma GN, Koufman JA (2001) The validity and reliability of the Reflux Finding Score (RFS). Laryngoscope 111:1313–1317PubMedCrossRef
11.
go back to reference Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal FT, Galmiche JP, Lundell L, Margulies M, Richter JE, Spechler SJ, Tytgat GN, Wallin L (1996) The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 111:85–92PubMedCrossRef Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal FT, Galmiche JP, Lundell L, Margulies M, Richter JE, Spechler SJ, Tytgat GN, Wallin L (1996) The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 111:85–92PubMedCrossRef
12.
go back to reference Kahrilas PJ (1996) Gastresophageal reflux disease. J Am Med Assoc 276:983–988CrossRef Kahrilas PJ (1996) Gastresophageal reflux disease. J Am Med Assoc 276:983–988CrossRef
13.
go back to reference Carrau RL, Khidr A, Crawley JA, Hillson EM, Davis JK, Pashos CL (2004) The impact of laryngopharyngeal reflux on patient-reported quality of life. Laryngoscope 114:670–674PubMedCrossRef Carrau RL, Khidr A, Crawley JA, Hillson EM, Davis JK, Pashos CL (2004) The impact of laryngopharyngeal reflux on patient-reported quality of life. Laryngoscope 114:670–674PubMedCrossRef
14.
go back to reference Williams RB, Szczesniak MM, Maclean JC, Brake HM, Cole IE, Cook IJ (2004) Predictors of outcome in an open label, therapeutic trial of high-dose omeprazole in laryngitis. Am J Gastroenterol 99:777–785PubMedCrossRef Williams RB, Szczesniak MM, Maclean JC, Brake HM, Cole IE, Cook IJ (2004) Predictors of outcome in an open label, therapeutic trial of high-dose omeprazole in laryngitis. Am J Gastroenterol 99:777–785PubMedCrossRef
15.
go back to reference Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I (1995) Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 30:1046–1052PubMedCrossRef Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I (1995) Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 30:1046–1052PubMedCrossRef
16.
go back to reference van Pinxteren B, Numans ME, Bonis PA, Lau J (2004) Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-esophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 4:CD002095PubMed van Pinxteren B, Numans ME, Bonis PA, Lau J (2004) Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-esophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 4:CD002095PubMed
17.
go back to reference Raghunath A, Hungin AP, Wooff D, Childs S (2003) Prevalence of Helicobacter pylori in patients with gastro-esophageal reflux disease: systematic review. Brit Med J 326:737PubMedCrossRef Raghunath A, Hungin AP, Wooff D, Childs S (2003) Prevalence of Helicobacter pylori in patients with gastro-esophageal reflux disease: systematic review. Brit Med J 326:737PubMedCrossRef
18.
go back to reference Koike T, Ohara S, Sekine H, Iijima K, Kato K, Shimosegawa T, Toyota T (1999) Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 94:3468–3472PubMedCrossRef Koike T, Ohara S, Sekine H, Iijima K, Kato K, Shimosegawa T, Toyota T (1999) Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 94:3468–3472PubMedCrossRef
Metadata
Title
Acid-suppression Therapy Offers Varied Laryngopharyngeal and Esophageal Symptom Relief in Laryngopharyngeal Reflux Patients
Authors
Nobuhiko Oridate
Hiroshi Takeda
Masahiro Asaka
Noriko Nishizawa
Yasushi Mesuda
Mika Mori
Yasushi Furuta
Satoshi Fukuda
Publication date
01-08-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-0114-9

Other articles of this Issue 8/2008

Digestive Diseases and Sciences 8/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.